Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Peabody Energy Corporation (NYSE: BTU) shareholders who lost money when the stock dropped following the company's Q1 2026 earnings release -- which...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) lost significant market capitalization on May 16, 2026, when the Company disclosed that its Phase 3 melanoma...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Hub Group, Inc. (NASDAQ: HUBG) told investors in its Q3 2025 report to expect full-year diluted EPS of $1.80 to $1.90. That guidance was built on...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Shareholders who held Upwork Inc. (NASDAQ: UPWK) stock lost approximately 19% of their investment value when shares plunged after the Company reported Q1...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Investors in Azenta, Inc. (NASDAQ: AZTA) suffered significant losses after the Company disclosed a $149 million goodwill impairment in its Q2 FY 2026...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Investors who held ZoomInfo Technologies Inc. (NASDAQ: GTM) shares lost roughly 33% of their value after the company disclosed a significant downward...
-
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Zoetis Inc. (NYSE: ZTS) investors lost approximately 21.5% of their investment on May 7, 2026, when shares collapsed after the company cut its FY 2026...
-
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- TriSalus Life Sciences Inc. (TLSI) shareholders suffered losses after the company reported Q1 2026 revenue of $8.9 million -- missing the $9.4 million...
-
Biogen stock fell approximately 6.4% in a single session after Phase 2 "CELIA" trial data for diranersen failed to meet its primary endpoint. NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc....
-
Prestige Consumer Healthcare executives projected organic revenue growth to decline 1.5-3.0%. In February, the target narrowed to a 3.0% decrease. Actual results had an even more significant decline...